Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Operating Leases (2021 - 2025)

Historic Operating Leases for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $98.5 million.

  • Roivant Sciences' Operating Leases rose 886.84% to $98.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $98.5 million, marking a year-over-year increase of 886.84%. This contributed to the annual value of $90.3 million for FY2025, which is 10063.97% up from last year.
  • Latest data reveals that Roivant Sciences reported Operating Leases of $98.5 million as of Q4 2025, which was up 886.84% from $89.8 million recorded in Q3 2025.
  • Roivant Sciences' Operating Leases' 5-year high stood at $98.5 million during Q4 2025, with a 5-year trough of $43.2 million in Q3 2024.
  • In the last 5 years, Roivant Sciences' Operating Leases had a median value of $61.2 million in 2021 and averaged $64.1 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 1706.35% in 2022, then surged by 10802.04% in 2025.
  • Quarter analysis of 5 years shows Roivant Sciences' Operating Leases stood at $62.1 million in 2021, then fell by 11.54% to $54.9 million in 2022, then dropped by 14.32% to $47.1 million in 2023, then surged by 92.27% to $90.5 million in 2024, then grew by 8.87% to $98.5 million in 2025.
  • Its last three reported values are $98.5 million in Q4 2025, $89.8 million for Q3 2025, and $90.3 million during Q2 2025.